BRCA wild-type
|
Ovarian Cancer
|
BRCA wild-type
|
Ovarian Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
BRCA wild-type
|
Breast Cancer
|
BRCA wild-type
|
Breast Cancer
|
olaparib Sensitive: C2 – Inclusion Criteria
|
olaparib Sensitive: C2 – Inclusion Criteria
|
BRCA wild-type
|
Triple Negative Breast Cancer
|
BRCA wild-type
|
Triple Negative Breast Cancer
|
olaparib + alpelisib Sensitive: C3 – Early Trials
|
olaparib + alpelisib Sensitive: C3 – Early Trials
|
BRCA wild-type
|
Breast Cancer
|
BRCA wild-type
|
Breast Cancer
|
talazoparib Sensitive: C3 – Early Trials
|
talazoparib Sensitive: C3 – Early Trials
|
BRCA wild-type
|
Triple Negative Breast Cancer
|
BRCA wild-type
|
Triple Negative Breast Cancer
|
MLN4924 Sensitive: D – Preclinical
|
MLN4924 Sensitive: D – Preclinical
|
BRCA wild-type
|
Ovarian Cancer
|
BRCA wild-type
|
Ovarian Cancer
|
olaparib + ART12 Sensitive: D – Preclinical
|
olaparib + ART12 Sensitive: D – Preclinical
|